DPI-221
From Wikipedia, the free encyclopedia
|
DPI-221
|
|
| Systematic (IUPAC) name | |
| 4-((αS)-α-((2S,5R)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C21H38FN3O |
| Mol. mass | 487.65 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
DPI-221 is a drug which is used in scientific research. It is a highly selective agonist for the δ-opioid receptor which produces less convulsions than most drugs from this family.[1]
[edit] References
- ^ Holt JD, Watson MJ, Chang JP, O'Neill SJ, Wei K, Pendergast W, Gengo PJ, Chang KJ. DPI-221 [4-((alpha-s)-alpha-((2s,5r)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: a novel nonpeptide delta receptor agonist producing increased micturition interval in normal rats. Journal of Pharmacology and Experimental Therapeutics. 2005 Nov;315(2):601-8. PMID 16020629

